NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 77 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q2 2013. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $4,000 | -81.0% | 2,473 | -77.9% | 0.00% | – |
| Q4 2014 | $21,000 | -97.1% | 11,175 | -96.8% | 0.00% | -100.0% |
| Q4 2013 | $733,000 | -79.8% | 354,200 | -74.1% | 0.01% | -85.7% |
| Q3 2013 | $3,620,000 | +44.1% | 1,366,100 | +45.2% | 0.04% | +29.6% |
| Q2 2013 | $2,512,000 | – | 941,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,046,431 | $19,861,000 | 4.55% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,702,002 | $8,847,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $38,000 | 0.03% |
| Hudock, Inc. | 27,500 | $36,000 | 0.02% |
| NOMURA HOLDINGS INC | 4,631,059 | $6,250,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 491,780 | $649,000 | 0.02% |
| Stratos Wealth Partners, LTD. | 45,535 | $60,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $24,000 | 0.01% |
| Tower Research Capital LLC (TRC) | 71,463 | $94,000 | 0.01% |
| SII INVESTMENTS INC/WI | 63,115 | $83,000 | 0.01% |